ABSTRACT
Advances in cancer detection and treatment strategies have improved survival rates significantly. The emphasis is now on the detection, prevention, and management of cancer treatment-related toxicities, which are recognized as a leading cause of morbidity and mortality in this select population.
This chapter is an overview of the current major societal guidelines from the European Society of Cardiology (2016), the American Society of Clinical Oncology (2016), the Canadian Cardiovascular Society (2016), the American Society of Echocardiography (2014), the European Association of Cardiovascular Imaging (2014), and the European Society of Medical Oncology (2012). These guidelines aim to provide some consensus on the identification and management of patients with cardiotoxicity.
Ultimately, morbidity and mortality related to cardiotoxicity can be reduced by early risk factor modification, timely identification of cardiotoxicity with imaging and/or serum biomarkers, initiation of guideline-directed cardioprotective medical therapy, prompt referral to appropriate specialists, and development of a multidisciplinary approach for individualized care. Ongoing research involving randomized controlled trials and large prospective registries is also required to optimize patient care in this complex subspecialty.
